1,373
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Blood pressure control measures and cardiovascular outcomes: a prospective hypertensive cohort

, , , , , , , , , & show all
Pages 228-235 | Received 20 Jun 2022, Accepted 02 Aug 2022, Published online: 19 Sep 2022

References

  • Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967.
  • Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels – updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34(4):613–622.
  • Benetos A, Thomas F, Bean KE, et al. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens. 2003;21(9):1635–1640.
  • Parati G, Ochoa JE, Lombardi C, et al. Blood pressure variability: assessment, predictive value, and potential as a therapeutic target. Curr Hypertens Rep. 2015;17(4):537.
  • Rosei EA, Chiarini G, Rizzoni D. How important is blood pressure variability? Eur Heart J Suppl. 2020;22(Supplement_E):E1–E6.
  • Tsioufis C. Blood pressure variability and cardiovascular prognosis. Many expectations but limited data. Hellenic J Cardiol. 2017;58(6):465–467.
  • Doumas M, Tsioufis C, Fletcher R, et al. Time in therapeutic range, as a determinant of all-cause mortality in patients with hypertension. J Am Heart Assoc. 2017;6:e007131.
  • Andrikou I, Dimitriadis K, Konstantinidis D, et al. Left ventricular mass versus pulse wave velocity as predictors of coronary artery disease in hypertensive patients: data from a 6-year-follow-up study. J Hum Hypertens. 2022;36(7):617–621.
  • Clase CM, Kiberd BA, Garg AX. Relationship between glomerular filtration rate and the prevalence of metabolic abnormalities: results from the third national health and nutrition examination survey (NHANES III). Nephron Clin Pract. 2007;105(4):c178–c184.
  • Mehlum MH, Liestøl K, Kjeldsen SE, et al. Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. Eur Heart J. 2018;39(24):2243–2251.
  • Chang TI, Reboussin DM, Chertow GM, et al. SPRINT research group. visit-to-visit office blood pressure variability and cardiovascular outcomes in SPRINT (systolic blood pressure intervention trial). Hypertension. 2017;70(4):751–758.
  • Mancia G, Messerli F, Bakris G, et al. Blood pressure control and improved cardiovascular outcomes in the international verapamil SR-Trandolapril study. Hypertension. 2007;50(2):299–305.
  • Fatani N, Dixon DL, Van Tassell BW, et al. Systolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension. J Am Coll Cardiol. 2021;77(10):1290–1299.
  • Grassi G, Quarti-Trevano F, Seravalle G, et al. Sympathetic neural mechanisms underlying attended and unattended blood pressure measurement. Hypertension. 2021;78(4):1126–1133.
  • Bakris G, Sternlicht H. Time in therapeutic range: redefining “optimal” blood pressure control. J Am Coll Cardiol. 2021;77(10):1300–1301.